Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
about
Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.Use, tolerability and compliance of spironolactone in the treatment of heart failure.Drug interactions with angiotensin receptor blockers.Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach.Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial)Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control studyLaboratory safety monitoring of chronic medications in ambulatory care settingsTolerability of spironolactone in patients with chronic heart failure -- a cautionary messageNew strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.Severe hyperkalemia requiring hospitalization: predictors of mortality.Well tolerated spironolactone-related hyponatremia.Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot)What is the risk of hyperkalaemia in heart failure?Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.Drug Class Combination-Associated Acute Kidney Injury.Survival after cardiopulmonary arrest with extreme hyperkalaemia and hypothermia in a patient with metformin-associated lactic acidosisDiabetes may be independent risk factor for hyperkalaemia.Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals.
P2860
Q30893153-013E4203-2D7A-4423-A385-FCA5D42E3FFAQ31013910-300E58D0-994A-49D9-AF5C-BADF268C4222Q33211891-B04C2DB6-CDFC-455C-A7B3-CE9A13B800E5Q33792583-936520AC-AB49-484E-AEC9-27208B9CC2E3Q34162275-B42A1248-8D77-416A-B7C5-96E0EF6E38ABQ34216532-44C66979-7A7F-4ED1-A9DB-F553288AACEDQ34281438-7484319A-31CF-48B8-BA0F-5C74077F63A8Q34722866-13B2968F-480C-4688-87EA-4CDEBDCAEBFEQ35826462-C9A22349-0DA5-4CBF-A900-7029B9396351Q36191021-13E06FD8-F0D9-45E8-BB36-99EC85B02C3CQ36712216-6C0DD034-7C35-4127-86B9-3FD3EF719158Q36902782-A4F96E8C-7E0F-4DC8-8080-2ADC47A33D77Q37133923-45EEE745-6310-4609-AF79-0815935C9346Q37133932-5FA294B5-8A4F-4D30-8F13-4DF2DD690410Q37902667-9615A042-5EB0-4AE5-BA47-0D4E2E921CB7Q38658657-DE4EB206-901A-4E09-9881-0717A5A0809AQ38889504-9AFE005C-4FA2-435A-A677-B5CD53D1B097Q41851189-CA7EAB3F-DCAF-4258-B861-C1C4C608B05CQ42967933-8B222018-8644-413A-A371-10C19854CFA2Q46169733-08A90C78-ACDB-4B63-9D34-0C5AD60F7647
P2860
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Interaction of spironolactone ...... lockers: analysis of 44 cases.
@ast
Interaction of spironolactone ...... lockers: analysis of 44 cases.
@en
type
label
Interaction of spironolactone ...... lockers: analysis of 44 cases.
@ast
Interaction of spironolactone ...... lockers: analysis of 44 cases.
@en
prefLabel
Interaction of spironolactone ...... lockers: analysis of 44 cases.
@ast
Interaction of spironolactone ...... lockers: analysis of 44 cases.
@en
P2093
P2860
P356
P1433
P1476
Interaction of spironolactone ...... lockers: analysis of 44 cases.
@en
P2093
Eike Wrenger
Jürgen C Frölich
Klaus H Neumann
Michael Moesenthin
Regina Müller
P2860
P304
P356
10.1136/BMJ.327.7407.147
P407
P50
P577
2003-07-01T00:00:00Z